Literature DB >> 34027599

Prognostic significance of tumor-infiltrating lymphocytes and macrophages in nasopharyngeal carcinoma: a systematic review and meta-analysis.

Weixing Liu1, Chunyi Zhang1, Gui Chen1, Xiao Liao1, Junyang Xie1, Tianhao Liang1, Wenjing Liao1, Lijuan Song1, Xiaowen Zhang2.   

Abstract

PURPOSE: Many studies have investigated the prognostic value of tumor-infiltrating lymphocytes (TILs) and tumor-infiltrating macrophages (TIMs) in patients with nasopharyngeal carcinoma (NPC), but the results remain controversial. Here, we performed a meta-analysis to evaluate the prognostic significance of TILs/TIMs in patients with NPC
METHODS: The study was registered with PROSPERO (CRD42021234078). PubMed, Embase, and Web of Science databases were searched up to Dec 30, 2020. We reviewed studies that evaluated the relationship between TILs/TIMs and overall survival (OS), disease-free survival (DFS), or progression-free survival (PFS) in NPC. For TILs, CD3, CD4, CD8, and FOXP3 were searched as T-cell markers, CD19 and CD20 as B-cell markers, and CD56 as a natural killer cell marker. For TIMs, CD68 and CD163 were searched as total and M2 macrophage markers, respectively.
RESULTS: In total, 19 studies with 3708 NPC were included in this meta-analysis. We found that high total numbers of TILs were significantly associated with favorable OS [hazard ratio (HR) 0.46, 95% confidence interval (CI) 0.38-0.57 and PFS (HR 0.48, 95% CI 0.38-0.62)]. In contrast, tumor infiltration by CD3+ T cells (HR 0.55, 95% CI 0.39-0.76), CD4+ T cells (HR 0.40, 95% CI 0.18-0.85), and CD8+ T cells (HR 0.56, 95% CI 0.34-0.93) correlated positively with OS. No significant relationship was found between survival and tumor infiltration by FOXP3+ T cells, CD68+ macrophages, or CD163+ macrophages.
CONCLUSION: Our findings revealed that tumor infiltration by CD3+ , CD4+ , and CD8+ T cells could be prognostic biomarkers in NPC.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Meta-analysis; Nasopharyngeal carcinoma; Prognosis; Tumor-infiltrating lymphocytes; Tumor-infiltrating macrophages

Mesh:

Year:  2021        PMID: 34027599     DOI: 10.1007/s00405-021-06879-2

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  46 in total

Review 1.  Nasopharyngeal carcinoma.

Authors:  Yu-Pei Chen; Anthony T C Chan; Quynh-Thu Le; Pierre Blanchard; Ying Sun; Jun Ma
Journal:  Lancet       Date:  2019-06-06       Impact factor: 79.321

Review 2.  Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective.

Authors:  Anne W M Lee; Brigette B Y Ma; Wai Tong Ng; Anthony T C Chan
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

Review 3.  Changes in the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging of Head and Neck Cancer: Rationale and Implications.

Authors:  Daniella Karassawa Zanoni; Snehal G Patel; Jatin P Shah
Journal:  Curr Oncol Rep       Date:  2019-04-17       Impact factor: 5.075

4.  PD-L1 Expression is Highly Associated with Tumor-Associated Macrophage Infiltration in Nasopharyngeal Carcinoma.

Authors:  Rui Deng; Juan Lu; Xiong Liu; Xiao-Hong Peng; Jie Wang; Xiang-Ping Li
Journal:  Cancer Manag Res       Date:  2020-11-12       Impact factor: 3.989

5.  Prognostic value of indoleamine 2,3-dioxygenase activity and expression in nasopharyngeal carcinoma.

Authors:  Ahlem Ben-Haj-Ayed; Adnène Moussa; Randa Ghedira; Sallouha Gabbouj; Souad Miled; Nadia Bouzid; Sameh Tebra-Mrad; Noureddine Bouaouina; Lotfi Chouchane; Abdelfattah Zakhama; Elham Hassen
Journal:  Immunol Lett       Date:  2015-11-26       Impact factor: 3.685

6.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

Review 7.  Macrophages as regulators of tumour immunity and immunotherapy.

Authors:  David G DeNardo; Brian Ruffell
Journal:  Nat Rev Immunol       Date:  2019-06       Impact factor: 53.106

Review 8.  The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis.

Authors:  Emma J de Ruiter; Marc L Ooft; Lot A Devriese; Stefan M Willems
Journal:  Oncoimmunology       Date:  2017-08-09       Impact factor: 8.110

9.  Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.

Authors:  Guoxuan Gao; Zihan Wang; Xiang Qu; Zhongtao Zhang
Journal:  BMC Cancer       Date:  2020-03-04       Impact factor: 4.430

10.  CD3+T-lymphocyte infiltration is an independent prognostic factor for advanced nasopharyngeal carcinoma.

Authors:  Nasser Al-Rajhi; Hussein Soudy; Shoaib A Ahmed; Tusneem Elhassan; Shamayel F Mohammed; Hatim A Khoja; Hazem Ghebeh
Journal:  BMC Cancer       Date:  2020-03-21       Impact factor: 4.430

View more
  3 in total

Review 1.  The emergence of tumor-infiltrating lymphocytes in nasopharyngeal carcinoma: Predictive value and immunotherapy implications.

Authors:  Liu Yang; Guohong Liu; Yirong Li; Yunbao Pan
Journal:  Genes Dis       Date:  2021-08-08

Review 2.  Nasopharyngeal Carcinoma and Its Microenvironment: Past, Current, and Future Perspectives.

Authors:  Zhi Yi Su; Pui Yan Siak; Chee-Onn Leong; Shiau-Chuen Cheah
Journal:  Front Oncol       Date:  2022-03-02       Impact factor: 6.244

3.  Prognostic Value of Tumor Infiltrating Lymphocytes in Nasopharyngeal Carcinoma Patients: Meta-Analysis.

Authors:  Birhanu Aberha Berele; Yuxiang Cai; Guifang Yang
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.